S

    Scynexis Inc (SCYX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.23
    -0.16 (-2.97%)

    Market Cap: $53.63M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +5.02%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.51
    Range$-0.56 - $-0.40
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.08-113.1%
    60d ago$-1.04-105.2%
    30d ago$-0.80-57.9%
    7d ago$-0.67-31.6%
    Current$-0.51
    Revenue Consensus
    $87000
    Range$0 - $261000
    3 analysts
    Dec 31, 2026
    EPS Consensus$-1.77
    Range$-1.89 - $-1.65
    2 analysts
    Revenue Consensus
    $375170
    Range$-9330 - $759670
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.77---
    Sep 26EST
    		-$-0.51---
    Jun 26
    		$-0.32$-0.40+20.00%Beat+71.4%
    Mar 26
    		$-3.36$-0.99-239.39%Miss-1876.5%
    Dec 25
    		$2.00$1.01+97.37%Beat+2322.2%
    Sep 25
    		$-0.17$-0.21+19.05%Beat+64.6%
    Jun 25
    		$-1.12$-1.52+26.32%Beat+53.3%
    Mar 25
    		$-0.17$-0.23+26.09%Beat-312.5%
    Dec 24
    		$-0.09N/A+59.09%Beat+76.9%
    Sep 24
    		$-0.48$-0.78+38.46%Beat-50.0%
    Jun 24
    		$-2.40$-1.62-48.15%Miss-112.2%
    Mar 24
    		$0.08N/A+105.16%Beat+111.3%
    Dec 23
    		$-0.39$-0.20-95.00%Miss+83.2%
    Sep 23
    		$-0.32N/A+72.65%Beat+93.5%
    Jun 23
    		$19.68$11.62+69.36%Beat+893.5%
    Mar 23
    		$-0.71$-0.28-153.57%Miss+47.8%
    Dec 22
    		$-2.32$-3.25+28.62%Beat-121.0%
    Sep 22
    		$-4.96$-3.94-25.89%Miss+10.8%
    Jun 22
    		$-2.48$-4.72+47.46%Beat-616.7%
    Mar 22
    		$-1.36N/A+78.06%Beat-126.7%
    Dec 21
    		$-1.05$-0.77-36.36%Miss+70.3%
    Sep 21
    		$-5.56$-5.64+1.42%Beat+39.0%
    Jun 21
    		$0.48N/A+110.17%Beat+111.3%
    Mar 21
    		$-0.60N/A+89.19%Beat+89.3%
    Dec 20
    		$-3.53$-0.81-335.80%Miss-60.5%
    Sep 20
    		$-9.12$-8.56-6.54%Miss+18.6%
    Jun 20
    		$-4.24N/A+55.46%Beat+65.4%
    Mar 20
    		$-5.60N/A+53.33%Beat+84.4%
    Dec 19
    		$-2.20$-1.90-15.79%Miss-120.0%
    Sep 19
    		$-11.20$-18.08+38.05%Beat-0.1%
    Jun 19
    		$-12.27$-15.60+21.35%Beat+33.3%
    Mar 19
    		$-35.84$-15.31-134.10%Miss-273.3%
    Dec 18
    		$-1.00$-1.42+29.58%Beat+63.0%
    Sep 18
    		$-11.19$-13.60+17.72%Beat+54.9%
    Jun 18
    		$-18.40$-14.06-30.87%Miss-43.7%
    Mar 18
    		$-9.60$-15.20+36.84%Beat+52.0%
    Dec 17
    		$-2.70$-2.85+5.26%Beat-440.0%
    Sep 17
    		$-24.80$-24.00-3.33%Miss-9.1%
    Jun 17
    		$-12.80$-22.40+42.86%Beat-
    Mar 17
    		$-20.00$-22.40+10.71%Beat-
    Dec 16
    		$-0.50N/A+86.74%Beat-
    Sep 16
    		$-22.74$-37.33+39.08%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.83EV/EBITDA0.05x
    Price/FCF-4.65xFCF Yield-21.52%
    Profitability
    Profit Margin-53.30%Operating Margin-3309.00%
    ROE-18.40%ROIC81.22%
    Financial Health
    Debt/Equity0.01xInterest Coverage11.32x
    Current Ratio9.65xQuick Ratio9.65x
    Trading Statistics
    Beta1.10Avg Volume111.17K
    52-Week High$10.4852-Week Low$3.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.29
    SMA 20$5.20
    SMA 50$4.60
    SMA 200$5.69
    EMA 10$5.28
    EMA 20$5.12
    EMA 50$4.97
    EMA 200$5.66

    MACD

    Line: 0.21Signal: 0.21Hist: 0.00

    ADX

    ADX: 40.5+DI: 26.1-DI: 9.4

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$5.11

    Bollinger Bands

    Upper Band$5.59
    Lower Band$4.81
    %B Position1507%(Upper)
    Band Width0.53

    RSI (14-Day)

    Neutral
    54.7

    Momentum Oscillators

    Stoch %K49.8
    Stoch %D58.3
    Williams %R-62.3
    ROC (10d)2.8%
    Momentum0.14
    CCI (20d)45.1
    MFI (14d)61.4

    Volatility Measures

    ATR (14d)$0.44(8.5%)
    StdDev (20d)0.20
    Hist Vol60.5%(High)

    Volume Flow

    VWAP$5.32
    OBV13.0M
    AD Line21.7B
    CMF (20d)-0.134

    Volume Metrics

    Avg Vol (20d)95.1K
    Vol Ratio0.4x(Low)
    VWMA (20d)$5.22

    Pivot Points

    R3$5.96
    R2$5.83
    R1$5.61
    Pivot Point$5.48
    S1$5.26
    S2$5.13
    S3$4.91

    Advanced Oscillators

    TSI18.15
    Ultimate Osc40.4
    KST201.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$235,000$0$18.65M$334,000$1.36M$257,000$977,000$660,000$736,000$1.37M$5.80M$1.76M
    Cost of Revenue$0$0N/A$0$0$0$0$0$0$0$15.20M$0
    Gross Profit$235,000$0$18.65M$334,000$1.36M$257,000$977,000$660,000$736,000$1.37M$-9,402,000$1.76M
    Operating Expenses$8.01M$16.94M$8.14M$8.74M$10.93M$8.87M$9.03M$10.98M$9.97M$10.88M$13.66M$11.86M
    R&D$3.89M$12.35M$4.55M$5.45M$7.14M$5.14M$4.31M$8.07M$6.81M$7.21M$10.59M$6.47M
    SG&A$4.12M$4.59M$3.60M$3.29M$3.78M$3.73M$4.72M$2.91M$3.17M$3.67M$3.59M$5.01M
    Operating Income$-7,775,000$-16,939,000$10.50M$-8,405,000$-9,561,000$-8,610,000$-8,052,000$-10,320,000$-9,237,000$-9,508,000$-23,065,000$-10,098,000
    Interest Income$685,000$535,000$437,000$454,000$510,000$776,000$861,000$1.02M$1.13M$1.28M$1.37M$1.26M
    Interest Expense$0$0$0$0$0$485,000$676,000$654,000$618,000$606,000$603,000$572,000
    Income Before Tax$7.40M$0$12.26M$-8,591,000$-6,885,000$0$-4,418,000$-3,203,000$-14,458,000$942,000$-19,448,000$-1,757,000
    Income Tax Expense$0$0$0$0$0$0$15,000$-395,000$0$531,000$138,000$0
    Net Income$7.40M$-21,299,000$12.26M$-8,591,000$-6,885,000$-5,391,000$-4,433,000$-2,808,000$-14,458,000$411,000$-19,586,000$-1,757,000
    EBITDA$6.64M$-21,875,000$11.76M$-9,143,000$-7,510,000$-5,569,000$-4,382,000$-3,605,000$-14,917,000$416,000$-20,343,000$-2,743,000
    EBIT$6.71M$-21,834,000$11.82M$-9,045,000$-7,395,000$-5,682,000$-4,603,000$-3,569,000$-14,970,000$268,000$-20,212,000$-2,448,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SCYX

    News

    SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SCYNEXIS, Inc. announced the grant of an inducement equity award to a new Senior Director, effective August 24, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The award consists of stock options to purchase 20,000 shares at an exercise price of $5.26, vesting over four years. This grant serves as a material inducement for the new employee's acceptance of employment with the clinical-stage biotechnology company.

    The Manila Times•8/25/26•
    Somewhat-Bullish

    SCYNEXIS, Inc. Earnings and Revenue – DUS:135

    SCYNEXIS, Inc. (DUS:135) reported strong financial results for the last quarter, with earnings per share significantly beating estimates by 224.34% at 0.55 EUR, and revenue reaching 205.77K EUR against an estimate of 70.34K EUR. For the upcoming quarter, analysts anticipate an EPS of -0.53 EUR and revenue of 85.01K EUR. The article provides a snapshot of the company's past performance and future expectations.

    TradingView•8/15/26•
    Bullish

    Revenue per share of SCYNEXis, Inc. – DUS:135

    This article displays the "Revenue per share" information for SCYNEXIS, Inc. (DUS:135) on the TradingView platform. It shows the period, value, change, and percentage change for this financial metric. The content also notes that the market is closed with no trades.

    TradingView•8/14/26•
    Neutral

    Results: SCYNEXIS, Inc. Confounded Analyst Expectations With A Surprise Profit

    SCYNEXIS, Inc. (NASDAQ:SCYX) surprised analysts by reporting a statutory profit of US$0.63 per share, significantly exceeding expectations of a loss, and revenues of US$235k. Following these strong quarterly results, analysts have increased their revenue forecasts for 2026 to US$1.73m and reduced the estimated loss per share to US$2.91. Consequently, the consensus price target for SCYNEXIS has risen by 8.9% to US$36.55, indicating an improved outlook from analysts despite a projected revenue decline compared to the wider industry.

    Simply Wall Street•8/14/26•
    Somewhat-Bullish

    Guggenheim raises Scynexis stock price target to $33 on drug potential

    Guggenheim raised its price target on Scynexis Inc. (NASDAQ:SCYX) to $33 from $24, maintaining a Buy rating, due to increased optimism for SCY-770 in autosomal dominant polycystic kidney disease. The firm projects $1.3 billion in peak annual U.S. sales for SCY-770 by 2032 and noted key upcoming catalysts including Phase 1 data for SCY-247 and SCY-770 in Q3 2026. This comes as Scynexis recently announced a 1-for-8 reverse stock split and Brookline Capital Markets reiterated its Buy rating with a $44.64 price target.

    Investing.com•8/13/26•
    Bullish

    Frequently Asked Questions About SCYX

    Does SCYX pay dividends?
    Scynexis Inc (SCYX) does not currently pay a regular dividend.
    What is SCYX's market cap?
    Scynexis Inc (SCYX) has a market capitalization of $53.63M with a current stock price of $5.23.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In